SK bioscienceLtd Future Growth
Future criteria checks 5/6
SK bioscienceLtd is forecast to grow earnings and revenue by 71.8% and 22.2% per annum respectively. EPS is expected to grow by 71.1% per annum. Return on equity is forecast to be -1.5% in 3 years.
Key information
71.8%
Earnings growth rate
71.1%
EPS growth rate
| Biotechs earnings growth | 83.6% |
| Revenue growth rate | 22.2% |
| Future return on equity | -1.5% |
| Analyst coverage | Good |
| Last updated | 30 Nov 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 467,544 | 13,360 | -71,412 | 250 | 6 |
| 12/31/2025 | 384,273 | -19,567 | -22,366 | 43,000 | 7 |
| 12/31/2024 | 221,250 | -49,384 | -70,453 | -105,500 | 6 |
| 9/30/2024 | 201,300 | -43,274 | -191,220 | -53,610 | N/A |
| 6/30/2024 | 371,479 | 27,435 | 17,716 | 135,175 | N/A |
| 3/31/2024 | 371,179 | 22,868 | -47,047 | 71,302 | N/A |
| 12/31/2023 | 369,506 | 22,318 | -20,949 | 29,346 | N/A |
| 9/30/2023 | 419,202 | 45,890 | -32,868 | 11,613 | N/A |
| 6/30/2023 | 278,429 | 18,276 | -162,430 | -123,743 | N/A |
| 3/31/2023 | 390,231 | 80,378 | -107,916 | -47,766 | N/A |
| 12/31/2022 | 456,726 | 122,452 | -201,448 | -124,958 | N/A |
| 12/31/2021 | 929,001 | 355,139 | 492,124 | 536,594 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A302440 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).
Earnings vs Market: A302440 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: A302440 is expected to become profitable in the next 3 years.
Revenue vs Market: A302440's revenue (22.2% per year) is forecast to grow faster than the KR market (9% per year).
High Growth Revenue: A302440's revenue (22.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A302440 is forecast to be unprofitable in 3 years.